Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript

Jennifer Simpson: Yeah. Absolutely. And thanks so much, Josh. So for the STK11 mutant, Phase 1, since the trial is open and screening for patients now, we would most likely have data towards the end of this year and that would then feed into the start of the Phase 2 portion. As of right now that is our current projection. We’re going to have to see how the enrollment goes. As a reminder, the STK11 mutant population of Non-Small Cell Lung Cancer, depending on which stores you look at ranges between 10% and 30% of lung cancers. But I will say market’s been actively screening. And so as enrollment starts we will keep everyone updated on the progress. But our hope right now is data from that by the end of the year. For the Ovarian Cancer, we have been working very closely with The Johns Hopkins University School of Medicine and looking to finalize that protocol and have that Phase 1 program opened by the first half of this year.

And it’s interesting because we’re looking at a number of trial designs. It could end up being a Phase 2, instead of a Phase 1, depending on which path we take. But we have a very engaged team. So we look forward to finalizing that and updating everyone accordingly.

Josh Korsen: Perfect. Thank you, for answering my questions. And thank you, for the update.

Jennifer Simpson: Sure. Thank you so much.

Operator: Thank you. This does conclude the Q&A session and also concludes today’s conference. You may disconnect your lines at this time, and thank you for your participation.